Lung cancer: A classic example of tumor escape and progression while providing opportunities for immunological intervention

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Jadus, Martin R ^a,b,c,d   Natividad, Josephine ^a   Mai, Anthony ^a   Ouyang, Yi ^a,b   Lambrecht, Nils ^a   Szabo, Sandor ^b,d   Ge, Lisheng ^a   Hoa, Neil ^a   Dacosta Iyer, Maria G ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Diagnostic and Molecular Medicine Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BCG VACCINE; CANCER VACCINE; CASPASE; CD133 ANTIGEN; DACLIZUMAB; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; EMEPEPIMUT S; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; IPILIMUMAB; MONOCLONAL ANTIBODY CC49; MULTIDRUG RESISTANCE PROTEIN; PEPTIDE VACCINE; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TOBACCO SMOKE; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTIBODY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG TREATMENT FAILURE; EOSINOPHIL; GAMMA DELTA T LYMPHOCYTE; GENE SILENCING; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHATIC DRAINAGE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SMOKING; SUPPRESSOR CELL; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; DISEASE COURSE; GENE THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; LYMPHOCYTE; PATHOLOGY; SURVIVAL RATE;

ANTIBODIES; CANCER VACCINES; DISEASE PROGRESSION; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTES; SURVIVAL RATE; TUMOR ESCAPE;

EID: 84864954385     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/160724     Document Type: Review

References (239)

1. Prins R. M., Soto H., Konkankit V., Odesa S. K., Eskin A., Yong W. H., Nelson S. F., Liau L. M., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy Clinical Cancer Research 2011 17 6 1603 1615
2. Gulley J. L., Drake C. G., Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research Clinical Cancer Research 2011 17 12 3884 3891
3. Hecht S. S., Tobacco smoke carcinogens and lung cancer Journal of the National Cancer Institute 1999 91 14 1194 1210 (Pubitemid 29357186)
4. Paez J. G., Jnne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F. J., Lindeman N., Boggon T. J., Naoki K., Sasaki H., Fujii Y., Eck M. J., Sellers W. R., Johnson B. E., Meyerson M., EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 (Pubitemid 38720929)
5. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Research 2004 64 24 8919 8923 (Pubitemid 39665498)
6. Wong D. W. S., Leung E. L. H., So K. K. T., Tam I. Y. S., Sihoe A. D. L., Cheng L. C., Ho K. K., Au J. S. K., Chung L. P., Wong M. P., The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 2009 115 8 1723 1733
7. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., Mun M. Y., Sakao Y., Okumura S., Nakagawa K., Soda M., Lim Choi Y., Mano H., Ishikawa Y., EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Modern Pathology 2009 22 4 508 515
8. Sun S., Schiller J. H., Gazdar A. F., Lung cancer in never smokersa different disease Nature Reviews Cancer 2007 7 10 778 790 (Pubitemid 47463669)
9. Ruffini E., Asioli S., Filosso P. L., Lyberis P., Bruna M. C., Macr L., Daniele L., Oliaro A., Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms Annals of Thoracic Surgery 2009 87 2 365 372
10. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., Dewhirst M. W., Bigner D. D., Rich J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 2006 444 7120 756 760 (Pubitemid 44949604)
11. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I. R., Lu L., Irvin D., Black K. L., Yu J. S., Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma Molecular Cancer 2006 5, article 67
12. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., Pratesi G., Fabbri A., Andriani F., Tinelli S., Roz E., Caserini R., Lo Vullo S., Camerini T., Mariani L., Delia D., Calabr E., Pastorino U., Sozzi G., Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment Proceedings of the National Academy of Sciences of the United States of America 2009 106 38 16281 16286
13. Hurt E. M., Farrar W. L., Purification and characterization of cancer stem cells Cancer Stem Cells 2009 Cambridge, Mass, USA Cambridge University Press 1 14
14. Lagadec C., Vlashi E., Donna L. D., Meng Y., Dekmezian C., Kim K., Pajonk F., Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment Breast Cancer Research 2010 12 1, article R13
15. Ambrosini G., Adida C., Altieri D. C., A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nature Medicine 1997 3 8 917 921 (Pubitemid 27353455)
16. Apolinario R. M., van der Valk P., De Jong J. S., Deville W., Van Ark-Otte J., Dingemans A. C., Van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G., Prognostic value of the expression of p53, bcl-2, and box oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer Journal of Clinical Oncology 1997 15 6 2456 2466 (Pubitemid 27251150)
17. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y., bcl-2 Protein in non-small-cell lung carcinoma The New England Journal of Medicine 1993 329 10 690 694 (Pubitemid 23252262)
18. Hariu H., Hirohashi Y., Torigoe T., Asanuma H., Hariu M., Tamura Y., Aketa K., Nabeta C., Nakanishi K., Kamiguchi K., Mano Y., Kitamura H., Kobayashi J., Tsukahara T., Shijubo N., Sato N., Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer Clinical Cancer Research 2005 11 3 1000 1009 (Pubitemid 40175747)
19. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., Coll J. L., Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors American Journal of Pathology 1996 149 6 1941 1952 (Pubitemid 26415213)
20. Olie R. A., Simes-Wst A. P., Baumann B., Leech S. H., Fabbro D., Stahel R. A., Zangemeister-Wittke U., A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy Cancer Research 2000 60 11 2805 2809 (Pubitemid 30395796)
21. Monz M., Rosell R., Felip E., Astudillo J., Snchez J. J., Maestre J., Martn C., Font A., Barnadas A., Abad A., A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers Journal of Clinical Oncology 1999 17 7 2100 2104 (Pubitemid 29318841)
22. Fine A., Janssen-Heininger Y., Soultanakis R. P., Swisher S. G., Uhal B. D., Apoptosis in lung pathophysiology American Journal of Physiology 2000 279 3 L423 L427
23. Joseph B., Lewensohn R., Zhivotovsky B., Role of apoptosis in the response of lung carcinomas to anti-cancer treatment Annals of the New York Academy of Sciences 2000 926 1 204 216 (Pubitemid 32050157)
24. Krysan K., Dalwadi H., Sharma S., Pld M., Dubinett S. M., Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer Cancer Research 2004 64 18 6359 6362 (Pubitemid 39297884)
25. Sheng H., Shao J., Morrow J. D., Beauchamp R. D., DuBois R. N., Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells Cancer Research 1998 58 2 362 366 (Pubitemid 28047080)
26. Joseph B., Ekedahl J., Sirzen F., Lewensohn R., Zhivotovsky B., Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma Biochemical and Biophysical Research Communications 1999 262 2 381 387 (Pubitemid 29429877)
27. Shivapurkar N., Reddy J., Matta H., Sathyanarayana U. G., Huang C. X., Toyooka S., Minna J. D., Chaudhary P. M., Gazdar A. F., Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification Oncogene 2002 21 55 8510 8514 (Pubitemid 36054892)
28. Shivapurkar N., Toyooka S., Eby M. T., Huang C. X., Sathyanarayana U. G., Cunningham H. T., Reddy J. L., Brambilla E., Takahashi T., Minna J. D., Chaudhary P. M., Gazdar A. F., Differential inactivation of caspase-8 in lung cancers Cancer Biology and Therapy 2002 1 1 65 69
29. Brambilla E., Gazzeri S., Lantuejoul S., Coll J. L., Moro D., Negoescu A., Brambilla C., p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer Clinical Cancer Research 1998 4 7 1609 1618 (Pubitemid 28304721)
30. Zchbauer-Mller S., Gazdar A. F., Minna J. D., Molecular pathogenesis of lung cancer Annual Review of Physiology 2002 64 681 708 (Pubitemid 34259246)
31. Pelosi G., Pasini F., Stenholm C. O., Pastorino U., Maisonneuve P., Sonzogni A., Maffini F., Pruneri G., Fraggetta F., Cavallon A., Roz E., Iannucci A., Bresaola E., Viale G., p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? Journal of Pathology 2002 198 1 100 109 (Pubitemid 34966213)
32. Schabath M. B., Wu X., Wei Q., Li G., Gu J., Spitz M. R., Combined effects of the p53 and p73 polymorphisms on lung cancer risk Cancer Epidemiology Biomarkers and Prevention 2006 15 1 158 161
33. Barker R. N., Erwig L. P., Pearce W. P., Devine A., Rees A. J., Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages Pathobiology 2000 67 5-6 302 305 (Pubitemid 30135929)
34. Voll R. E., Herrmann M., Roth E. A., Stach C., Kalden J. R., Girkontaite I., Immunosuppressive effects of apoptotic cells Nature 1997 390 6658 350 351
35. Steinman R. M., Turley S., Mellman I., Inaba K., The induction of tolerance by dendritic cells that have captured apoptotic cells Journal of Experimental Medicine 2000 191 3 411 416
36. Sauter B., Albert M. L., Francisco L., Larsson M., Somersan S., Bhardwaj N., Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells Journal of Experimental Medicine 2000 191 3 423 433
37. Fadok V. A., Bratton D. L., Konowal A., Freed P. W., Westcott J. Y., Henson P. M., Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-, PGE2, and PAF Journal of Clinical Investigation 1998 101 4 890 898 (Pubitemid 28096086)
38. Fonseca C., Dranoff G., Capitalizing on the immunogenicity of dying tumor cells Clinical Cancer Research 2008 14 6 1603 1608 (Pubitemid 351469443)
39. Ullrich E., Bonmort M., Mignot G., Kroemer G., Zitvogel L., Tumor stress, cell death and the ensuing immune response Cell Death and Differentiation 2008 15 1 21 28 (Pubitemid 350286169)
40. Kepp O., Galluzzi L., Martins I., Schlemmer F., Adjemian S., Michaud M., Sukkurwala A. Q., Menger L., Zitvogel L., Kroemer G., Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy Cancer and Metastasis Reviews 2011 30 1 61 69
41. Young L. C., Campling B. G., Cole S. P. C., Deeley R. G., Gerlach J. H., Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels Clinical Cancer Research 2001 7 6 1798 1804 (Pubitemid 32708651)
42. Young L. C., Campling B. G., Voskoglou-Nomikos T., Cole S. P. C., Deeley R. G., Gerlach J. H., Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response Clinical Cancer Research 1999 5 3 673 680 (Pubitemid 29131979)
43. Mahaffey C. M., Mahaffey N. C., Holland W., Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma Journal of Thoracic Oncology 2012 7 1 34 39
44. Triller N., Koroec P., Kern I., Konik M., Debeljak A., Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease Lung Cancer 2006 54 2 235 240 (Pubitemid 44764911)
45. Sullivan J. P., Spinola M., Dodge M., Raso M. G., Behrens C., Gao B., Schuster K., Shao C., Larsen J. E., Sullivan L. A., Honorio S., Xie Y., Scaglioni P. P., DiMaio J. M., Gazdar A. F., Shay J. W., Wistuba I. I., Minna J. D., Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling Cancer Research 2010 70 23 9937 9948
46. Griguer C. E., Oliva C. R., Gobin E., Marcorelles P., Benos D. J., Lancaster J. R., Gillespie G. Y., CD133 is a marker of bioenergetic stress in human glioma PLoS ONE 2008 3 11, article e3655
47. Angelastro J. M., Lamé M. W., Overexpression of CD133 promotes drug resistance in C6 glioma cells Molecular Cancer Research 2010 8 8 1105 1115
48. Hirschmann-Jax C., Foster A. E., Wulf G. G., Nuchtern J. G., Jax T. W., Gobel U., Goodell M. A., Brenner M. K., A distinct side population of cells with high drug efflux capacity in human tumor cells Proceedings of the National Academy of Sciences of the United States of America 2004 101 39 14228 14233 (Pubitemid 39305058)
49. McLemore T. L., Hubbard W. C., Litterst C. L., Liu M. C., Miller S., McMahon N. A., Eggleston J. C., Boyd M. R., Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients Cancer Research 1988 48 11 3140 3147
50. Funk C. D., Prostaglandins and leukotrienes: advances in eicosanoid biology Science 2001 294 5548 1871 1875 (Pubitemid 33101574)
51. Cao Y., Prescott S. M., Many actions of cyclooxygenase-2 in cellular dynamics and in cancer Journal of Cellular Physiology 2002 190 3 279 286 (Pubitemid 34111968)
52. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimki A., Expression of cyclooxygenase-2 in human lung carcinoma Cancer Research 1998 58 22 4997 5001 (Pubitemid 28521147)
53. Schreinemachers D. M., Everson R. B., Aspirin use and lung, colon, and breast cancer incidence in a prospective study Epidemiology 1994 5 2 138 146 (Pubitemid 24073387)
54. Hata A. N., Breyer R. M., Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacology and Therapeutics 2004 103 2 147 166 (Pubitemid 39209041)
55. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R. L., Morrow J. D., Shyr Y., Boothby M., Joyce S., Carbone D. P., Breyer R. M., Cancer-associated immunodefidency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor Journal of Clinical Investigation 2003 111 5 727 735 (Pubitemid 36278591)
56. Kim J. I., Lakshmikanthan V., Frilot N., Daaka Y., Prostaglandin E2 promotes lung cancer cell migration via EP4- /Arrestin1-c-Src signalsome Molecular Cancer Research 2010 8 4 569 577
57. Dohadwala M., Batra R. K., Luo J., Lin Y., Krysan K., Pld M., Sharma S., Dubinett S. M., Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion The Journal of Biological Chemistry 2002 277 52 50828 50833 (Pubitemid 36042248)
58. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G. J., Sharma S., Huang M., Pld M., Batra R. K., Dubinett S. M., Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44 The Journal of Biological Chemistry 2001 276 24 20809 20812
59. Krysan K., Reckamp K. L., Dalwadi H., Sharma S., Rozengurt E., Dohadwala M., Dubinett S. M., Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner Cancer Research 2005 65 14 6275 6281 (Pubitemid 40994413)
60. Watson J., The influence of intracellular levels of cyclic nucleotides on cell proliferation and the induction of antibody synthesis Journal of Experimental Medicine 1975 141 1 97 111
61. Kammer G. M., The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response Immunology Today 1988 9 7-8 222 229
62. Huang M., Sharma S., Mao J. T., Dubinett S. M., Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production Journal of Immunology 1996 157 12 5512 5520 (Pubitemid 126448972)
63. Huang M., Stolina M., Sharma S., Mao J. T., Zhu L., Miller P. W., Wollman J., Herschman H., Dubinett S. M., Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production Cancer Research 1998 58 6 1208 1216 (Pubitemid 28183210)
64. Sharma S., Stolina M., Lin Y., Gardner B., Miller P. W., Kronenberg M., Dubinett S. M., T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function Journal of Immunology 1999 163 9 5020 5028 (Pubitemid 29501270)
65. Miotto D., Lo Cascio N., Stendardo M., Querzoli P., Pedriali M., De Rosa E., Fabbri L. M., Mapp C. E., Boschetto P., CD8 + T cells expressing IL-10 are associated with a favourable prognosis in lung cancer Lung Cancer 2010 69 3 355 360
66. Mocellin S., Marincola F. M., Young H. A., Interleukin-10 and the immune response against cancer: a counterpoint Journal of Leukocyte Biology 2005 78 5 1043 1051 (Pubitemid 41572467)
67. Lopez M. V., Adris S. K., Bravo A. I., Chernajovsky Y., Podhajcer O. L., IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis Journal of Immunology 2005 175 9 5885 5894 (Pubitemid 41508073)
68. Huang M., Wang J., Lee P., Sharma S., Mao J. T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S. M., Human non-small cell lung cancer cells express a type 2 cytokine pattern Cancer Research 1995 55 17 3847 3853
69. Pine S. R., Mechanic L. E., Enewold L., Chaturvedi A. K., Katki H. A., Zheng Y. L., Bowman E. D., Engels E. A., Caporaso N. E., Harris C. C., Increased levels of circulating interleukin 6, interleukin 8, c-reactive protein, and risk of lung cancer Journal of the National Cancer Institute 2011 103 14 1112 1122
70. Wjcik E., Jakubowicz J., Skotnicki P., Sas-Korczyska B., Kulpa J. K., IL-6 and VEGF in small cell lung cancer patients Anticancer Research 2010 30 5 1773 1778
71. Salven P., Ruotsalainen T., Mattson K., Joensuu H., High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer International Journal of Cancer 1998 79 2 144 146 (Pubitemid 28201685)
72. Salven P., Menp H., Orpana A., Alitalo K., Joensuu H., Serum vascular endothelial growth factor is often elevated in disseminated cancer Clinical Cancer Research 1997 3 5 647 651 (Pubitemid 27244329)
73. Kajita T., Ohta Y., Kimura K., Tamura M., Tanaka Y., Tsunezuka Y., Oda M., Sasaki T., Watanabe G., The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer British Journal of Cancer 2001 85 2 255 260 (Pubitemid 32695748)
74. Delmotte P., Martin B., Paesmans M., Berghmans T., Mascaux C., Meert A. P., Steels E., Verdebout J. M., Lafitte J. J., Soulier J. P., The role of vascular endothelial growth factor in the survival of patients with lung cancer: a systematic literature review and meta-analysis Revue des Maladies Respiratoires 2002 19 5 577 584 (Pubitemid 35303646)
75. Volm M., Koomgi R., Mattern J., Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer International Journal of Cancer 1997 74 1 64 68 (Pubitemid 27157857)
76. Tanno S., Ohsaki Y., Nakanishi K., Toyoshima E., Kikuchi K., Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3 Lung Cancer 2004 46 1 11 19 (Pubitemid 39201379)
77. Gabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S., Kavanaugh D., Carbone D. P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nature Medicine 1996 2 10 1096 1103 (Pubitemid 26338628)
78. Lee S. J., Lee S. Y., Jeon H. S., Park S. H., Jang J. S., Lee G. Y., Son J. W., Kim C. H., Lee W. K., Kam S., Park R. W., Park T. I., Kang Y. M., Kim I. S., Jung T. H., Park J. Y., Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer Cancer Epidemiology Biomarkers and Prevention 2005 14 3 571 575 (Pubitemid 40489197)
79. Bierie B., Moses H. L., Tumour microenvironmentTGF : the molecular Jekyll and Hyde of cancer Nature Reviews Cancer 2006 6 7 506 520 (Pubitemid 43980540)
80. Prud'homme G. J., Pathobiology of transforming growth factor in cancer, fibrosis and immunologic disease, and therapeutic considerations Laboratory Investigation 2007 87 11 1077 1091
81. Hasegawa Y., Takanashi S., Kanehira Y., Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma Cancer 2001 91 5 964 971
82. Jakowlew S. B., Mathias A., Chung P., Moody T. W., Expression of transforming growth factor ligand and receptor messenger RNAs in lung cancer cell lines Cell Growth and Differentiation 1995 6 4 465 476
83. Hougaard S., Nrgaard P., Abrahamsen N., Moses H. L., Spang-Thomsen M., Poulsen H. S., Inactivation of the transforming growth factor type II receptor in human small cell lung cancer cell lines British Journal of Cancer 1999 79 7-8 1005 1011 (Pubitemid 29087867)
84. Damstrup L., Rygaard K., Spang-Thomsen M., Poulsen H. S., Expression of transforming growth factor (TGF ) receptors and expression of TGF 1, TGF 2 and TGF 3 in human small cell lung cancer cell lines British Journal of Cancer 1993 67 5 1015 1021 (Pubitemid 23147495)
85. Kim T. K., Mo E. K., Yoo C. G., Lee C. T., Han S. K., Shim Y. S., Kim Y. W., Alteration of cell growth and morphology by overexpression of transforming growth factor type II receptor in human lung adenocarcinoma cells Lung Cancer 2001 31 2-3 181 191 (Pubitemid 32107015)
86. de Jonge R. R., Garrigue-Antar L., Vellucci V. F., Reiss M., Frequent inactivation of the transforming growth factor type ii receptor in small-cell lung carcinoma cells Oncology Research 1997 9 2 89 98 (Pubitemid 127825889)
87. Jakowlew S. B., Mathias A., Chung P., Moody T. W., Expression of transforming growth factor ligand and receptor messenger RNAs in lung cancer cell lines Cell Growth and Differentiation 1995 6 4 465 476
88. Fischer J. R., Darjes H., Lahm H., Schindel M., Drings P., Krammer P. H., Constitutive secretion of bioactive transforming growth factor 1 by small cell lung cancer cell lines European Journal of Cancer Part A 1994 30 14 2125 2129
89. Letterio J. J., Roberts A. B., Regulation of immune responses by TGF- Annual Review of Immunology 1998 16 137 161 (Pubitemid 28183362)
90. Kang H. G., Chae M. H., Park J. M., Kim E. J., Park J. H., Kam S., Cha S. I., Kim C. H., Park R. W., Park S. H., Kim Y. L., Kim I. S., Jung T. H., Park J. Y., Polymorphisms in TGF- 1 gene and the risk of lung cancer Lung Cancer 2006 52 1 1 7 (Pubitemid 43340192)
91. Sharma S., Yang S. C., Zhu L., Reckamp K., Gardner B., Baratelli F., Huang M., Batra R. K., Dubinett S. M., Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4 + CD25 + T regulatory cell activities in lung cancer Cancer Research 2005 65 12 5211 5220 (Pubitemid 40827331)
92. Sinha P., Clements V. K., Fulton A. M., Ostrand-Rosenberg S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Research 2007 67 9 4507 4513 (Pubitemid 46815102)
93. Hama A., Pignon P., Raimbaud I., Human TH17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN- secreting cells as they differentiate into effector T cells in vivo Cancer Research 2012 72 5 1 5
94. Ben-Sasson S. Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., Dinarello C. A., Paul W. E., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation Proceedings of the National Academy of Sciences of the United States of America 2009 106 17 7119 7124
95. Lee W. W., Kang S. W., Choi J., Lee S. H., Shah K., Eynon E. E., Flavell R. A., Kang I., Regulating human Th17 cells via differential expression of IL-1 receptor Blood 2010 115 3 530 540
96. Boniface K., Bak-Jensen K. S., Li Y., Blumenschein W. M., McGeachy M. J., McClanahan T. K., McKenzie B. S., Kastelein R. A., Cua D. J., De Malefyt R. W., Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling Journal of Experimental Medicine 2009 206 3 535 548
97. Chizzolini C., Chicheportiche R., Alvarez M., De Rham C., Roux-Lombard P., Ferrari-Lacraz S., Dayer J. M., Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion Blood 2008 112 9 3696 3703
98. Martin-Orozco N., Muranski P., Chung Y., Yang X. O., Yamazaki T., Lu S., Hwu P., Restifo N. P., Overwijk W. W., Dong C., T helper 17 cells promote cytotoxic T cell activation in tumor immunity Immunity 2009 31 5 787 798
99. Ji Y., Zhang W., Th17 cells: positive or negative role in tumor? Cancer Immunology, Immunotherapy 2010 59 7 979 987
100. Ho P. P., Steinman L., The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease Cell Research 2008 18 6 605 608 (Pubitemid 351793116)
101. Martey C. A., Baglole C. J., Gasiewicz T. A., Sime P. J., Phipps R. P., The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts American Journal of Physiology 2005 289 3 L391 L399
102. Chang J. T., Chang H., Chen P. H., Lin S. L., Lin P., Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas Clinical Cancer Research 2007 13 1 38 45 (Pubitemid 46121850)
103. Baglole C. J., Maggirwar S. B., Gasiewicz T. A., Thatcher T. H., Phipps R. P., Sime P. J., The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF- B family member RelB The Journal of Biological Chemistry 2008 283 43 28944 28957
104. Nguyen N. T., Kimura A., Nakahama T., Chinen I., Masuda K., Nohara K., Fujii-Kuriyama Y., Kishimoto T., Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism Proceedings of the National Academy of Sciences of the United States of America 2010 107 46 19961 19966
105. Mahnke K., Schnfeld K., Fondel S., Ring S., Karakhanova S., Wiedemeyer K., Bedke T., Johnson T. S., Storn V., Schallenberg S., Enk A. H., Depletion of CD4 + CD25 + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro International Journal of Cancer 2007 120 12 2723 2733 (Pubitemid 46651297)
106. Zheng S. G., Wang J. H., Gray J. D., Soucier H., Horwitz D. A., Natural and induced CD4 + CD25 + cells educate CD4 + CD25 - cells to develop suppressive activity: the role of IL-2, TGF-, and IL-10 Journal of Immunology 2004 172 9 5213 5221 (Pubitemid 38542018)
107. Petersen R. P., Campa M. J., Sperlazza J., Conlon D., Joshi M. B., Harpole D. H., Patz E. F., Tumor infiltrating FOXP3 + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients Cancer 2006 107 12 2866 2872 (Pubitemid 44937041)
108. Granville C. A., Memmott R. M., Balogh A., A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis Plos ONE 2009 4 3, article e5061
109. Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H., Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation Journal of Immunology 2002 168 9 4272 4276 (Pubitemid 34441324)
110. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
111. Sharma M. D., Hou D. Y., Liu Y., Koni P. A., Metz R., Chandler P., Mellor A. L., He Y., Munn D. H., Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes Blood 2009 113 24 6102 6111
112. Lb S., Knigsrainer A., Zieker D., Brcher B. L. D. M., Rammensee H. G., Opelz G., Terness P., IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism Cancer Immunology, Immunotherapy 2009 58 1 153 157
113. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B. J., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nature Medicine 2003 9 10 1269 1274 (Pubitemid 37279849)
114. Prendergast G. C., Immune escape as a fundamental trait of cancer: focus on IDO Oncogene 2008 27 28 3889 3900 (Pubitemid 351913639)
115. Karanikas J. V., Zamanakou M., Kerenidi T., Dahabreh J., Hevas A., Nakou M., Gourgoulianis K. I., Germenis A. E., Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer Cancer Biology and Therapy 2007 6 8 1258 1262 (Pubitemid 351590380)
116. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A. L., Munn D. H., Antonia S. J., Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection International Journal of Cancer 2002 101 2 151 155 (Pubitemid 34970907)
117. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A., Ratto G. B., Melioli G., Frumento G., Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer Neoplasia 2005 7 4 390 396 (Pubitemid 40664228)
118. Leach D. R., Krummel M. F., Allison J. P., Enhancement of antitumor immunity by CTLA-4 blockade Science 1996 271 5256 1734 1736 (Pubitemid 26102823)
119. Montero A. J., Diaz-Montero C. M., Kyriakopoulos C. E., Myeloid-derived suppressor cells in cancer patients: a clinical perspective Journal of Immunotherapy 2012 35 2 107 115
120. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews Immunology 2009 9 3 162 174
121. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer Journal of Immunology 2009 182 8 4499 4506
122. Jadus M. R., Parkman R., The selective growth of murine newborn-derived suppressor cells and their probable mode of action Journal of Immunology 1986 136 3 783 792 (Pubitemid 16146355)
123. Rodriguez P. C., Hernandez C. P., Quiceno D., Dubinett S. M., Zabaleta J., Ochoa J. B., Gilbert J., Ochoa A. C., Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma Journal of Experimental Medicine 2005 202 7 931 939 (Pubitemid 41396893)
124. Pardoll D., Drake C., Immunotherapy earns its spot in the ranks of cancer therapy Journal of Experimental Medicine 2012 209 2 201 209
125. Talmadge J. E., Hood K. C., Zobel L. C., Shafer L. R., Coles M., Toth B., Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion International Immunopharmacology 2007 7 2 140 151 (Pubitemid 46043318)
126. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., Suttmann H., Schenck M., Welling J., Zabel P., Lang S., Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties Journal of Leukocyte Biology 2011 89 2 311 317
127. Liu Y., Van Ginderachter J. A., Brys L., De Baetselier P., Raes G., Geldhof A. B., Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells Journal of Immunology 2003 170 10 5064 5074 (Pubitemid 36554736)
128. Corraliza I. M., Soler G., Eichmann K., Modolell M., Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages Biochemical and Biophysical Research Communications 1995 206 2 667 673
129. Ochoa A. C., Zea A. H., Hernandez C., Rodriguez P. C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma Clinical Cancer Research 2007 13 2 721s 726s
130. Modolell M., Corraliza I. M., Link F., Soler G., Eichmann K., Reciprocal regulation of the nitric oxide synthase-arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines European Journal of Immunology 1995 25 4 1101 1104
131. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., Ouyang G. F., Okada M., Balazs M., Adany R., Shibata T., Takami T., Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics Journal of Leukocyte Biology 2008 83 5 1136 1144 (Pubitemid 351960345)
132. Choi K. L., Maier T., Holda J. H., Claman H. N., Suppression of cytotoxic T-cell generation by natural suppressor cells from mice with GVHD is partially reserved by indomethacin Cellular Immunology 1988 112 2 271 278
133. Baba T., Hanagiri T., Ichiki Y., Kuroda K., Shigematsu Y., Mizukami M., Sugaya M., Takenoyama M., Sugio K., Yasumoto K., Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B Cancer Science 2007 98 11 1795 1802 (Pubitemid 47487918)
134. Doyle A., Martin W. J., Funa K., Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer Journal of Experimental Medicine 1985 161 5 1135 1151 (Pubitemid 15011330)
135. Singal D. P., Ye M., Qiu X., Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines International Journal of Cancer 1996 68 5 629 636 (Pubitemid 26414525)
136. Chen H. L., Gabrilovich D., Virman A., Structural and functional analysis of 2 microglobulin abnormalities in human lung and breast cancer International Journal of Cancer 1996 67 6 756 763 (Pubitemid 26348802)
137. Chen H. L., Gabrilovich D., Tampé R., Girgis K. R., Nadaf S., Carbone D. P., A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer Nature Genetics 1996 13 2 210 213 (Pubitemid 26000442)
138. Johnsen A., France J., Sy M. S., Harding C. V., Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines Cancer Research 1998 58 16 3660 3667 (Pubitemid 28376566)
139. Ruff M. R., Farrar W. L., Pert C. B., Interferon and granulocyte/ macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines Proceedings of the National Academy of Sciences of the United States of America 1986 83 17 6613 6617 (Pubitemid 17174785)
140. Traversari C., Meazza R., Coppolecchia M., Basso S., Verrecchia A., van der Bruggen P., Ardizzoni A., Gaggero A., Ferrini S., IFN- gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer Gene Therapy 1997 4 10 1029 1035 (Pubitemid 27469932)
141. Marley G. M., Doyle L. A., Ordonez J. V., Sisk A., Hussain A., Chiu Yen R. W., Potentiation of interferon induction of class I major histocompatibility complex antigen expression of human tumor necrosis factor in small cell lung cancer cell lines Cancer Research 1989 49 22 6232 6236 (Pubitemid 20000914)
142. Garrido C., Romero I., Berruguilla E., Cancela B., Algarra I., Collado A., Garca-Lora A., Garrido F., Immunotherapy eradicates metastases with reversible defects in MHC class I expression Cancer Immunology, Immunotherapy 2011 60 9 1257 1268
143. Kikuchi E., Yamazaki K., Nakayama E., Sato S., Uenaka A., Yamada N., Oizumi S., Dosaka-Akita H., Nishimura M., Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens Cancer Immunity 2008 8, article 13
144. Aladin F., Lautscham G., Humphries E., Coulson J., Blake N., Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8 + T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER Cancer Immunology, Immunotherapy 2007 56 8 1143 1152 (Pubitemid 46763929)
145. Kikuchi E., Yamazaki K., Torigoe T., Cho Y., Miyamoto M., Oizumi S., Hommura F., Dosaka-Akita H., Nishimura M., HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer Cancer Science 2007 98 9 1424 1430 (Pubitemid 47243535)
146. Rouas-Freiss N., Moreau P., Ferrone S., Carosella E. D., HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Research 2005 65 22 10139 10144 (Pubitemid 41743699)
147. Pietra G., Romagnani C., Manzini C., Moretta L., Mingari M. C., The emerging role of HLA-E-restricted CD8 + T lymphocytes in the adaptive immune response to pathogens and tumors Journal of Biomedicine and Biotechnology 2010 2010 8
148. Lin A., Zhang X., Ruan Y. Y., Wang Q., Zhou W. J., Yan W. H., HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer Lung Cancer 2011 74 3 504 509
149. Pangault C., Le Friec G., Caulet-Maugendre S., Léna H., Amiot L., Guilloux V., Onno M., Fauchet R., Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases Human Immunology 2002 63 2 83 90 (Pubitemid 34132584)
150. Urosevic M., Kurrer M. O., Kamarashev J., Mueller B., Weder W., Burg G., Stahel R. A., Dummer R., Trojan A., Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production American Journal of Pathology 2001 159 3 817 824 (Pubitemid 32847172)
151. Yie S. M., Yang H., Ye S. R., Li K., Dong D. D., Lin X. M., Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer Lung Cancer 2007 58 2 267 274 (Pubitemid 47516690)
152. Schtt P., Schtt B., Switala M., Bauer S., Stamatis G., Opalka B., Eberhardt W., Schuler M., Horn P. A., Rebmann V., Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients Human Immunology 2010 71 5 489 495
153. Ristich V., Liang S., Zhang W., Wu J., Horuzsko A., Tolerization of dendritic cells by HLA-G European Journal of Immunology 2005 35 4 1133 1142 (Pubitemid 40542220)
154. Allard M., Oger R., Vignard V., Percier J. M., Fregni G., Périer A., Caignard A., Charreau B., Bernardeau K., Khammari A., Dréno B., Gervois N., Serum soluble HLA-E in Melanoma: a new potential immune-related marker in cancer PLoS ONE 2011 6 6, article e21118
155. Nagata S., Apoptosis by death factor Cell 1997 88 3 355 365 (Pubitemid 27131377)
156. Janmaat M. L., Kruyt F. A. E., Rodriguez J. A., Giaccone G., Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clinical Cancer Research 2003 9 6 2316 2326 (Pubitemid 36687658)
157. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A., Human lung carcinomas express Fas ligand Cancer Research 1997 57 6 1007 1012 (Pubitemid 27138590)
158. Restifo N. P., Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape Nature Medicine 2000 6 5 493 495 (Pubitemid 30305889)
159. Zhang Y., Liu Q., Zhang M., Yu Y., Liu X., Cao X., Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE Journal of Immunology 2009 182 6 3801 3808
160. Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A., Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 1998 396 6712 699 703 (Pubitemid 29003951)
161. Gomez G. G., Kruse C. A., Mechanisms of malignant glioma immune resistance and sources of immunosuppression Gene Therapy and Molecular Biology 2006 10 1 133 146 (Pubitemid 351976185)
162. Hickey M. J., Malone C. C., Erickson K. L., Cellular and vaccine therapeutic approaches for gliomas Journal of Translational Medicine 2010 8, article 100
163. Ge L., Hoa N., Bota D. A., Natividad J., Howat A., Jadus M. R., Immunotherapy of brain cancers: the past, the present, and future directions Clinical and Developmental Immunology 2010 2010 19
164. Lamm D. L., Thor D. E., Harris S. C., Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer Journal of Urology 1980 124 1 38 42 (Pubitemid 10032428)
165. Millar J. W., Roscoe P., Pearce S. J., Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma Thorax 1982 37 1 57 60 (Pubitemid 12192070)
166. Patard J. J., Saint F., Velotti F., Abbou C. C., Chopin D. K., Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: a review Urological Research 1998 26 3 155 159 (Pubitemid 28305378)
167. Jansen H. M., De Gast G. C., Esselink M. T., Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immunereactivity in relation to immunostimulation (preliminary results in a controlled trial) Thorax 1978 33 4 429 438 (Pubitemid 8406620)
168. Kaufmann M., Stjernsward J., Zimmermann A., Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected Stage I and II non-small cell carcinoma of the lung Journal of Thoracic and Cardiovascular Surgery 1985 89 6 842 847 (Pubitemid 15012852)
169. O'Brien M. E. R., Anderson H., Kaukel E., O'Byrne K., Pawlicki M., von Pawel J., Reck M., Ellis P., Hickish T., Nicolson M., Woll P., Dunlop D., Falk S., Johnson P., Collinson M., Hatton M., Gilligan D., Middleton G., Reck M., Loddenkemper R., Deperman K., Aigner K., Pirker R., Rothmund J., Tujakowski J., Krzakowski M., Ramlau R., Crawford B., Massaro J., Cross A., Tuckwell N., Kennard D., Povey J., SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Annals of Oncology 2004 15 6 906 914 (Pubitemid 39004346)
170. Stanford J. L., Stanford C. A., O'Brien M. E. R., Grange J. M., Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung European Journal of Cancer 2008 44 2 224 227
171. Hollinshead A., Stewart T. H. M., Takita H., Dalbow M., Concannon J., Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens Cancer 1987 60 6 1249 1262 (Pubitemid 17152903)
172. Forero A., Meredith R. F., Khazaeli M. B., Shen S., Grizzle W. E., Carey D., Busby E., LoBuglio A. F., Robert F., Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration Cancer Biotherapy and Radiopharmaceuticals 2005 20 5 467 478 (Pubitemid 41619138)
173. Grant S. C., Kris M. G., Houghton A. N., Chapman P. B., Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette- Guerin Clinical Cancer Research 1999 5 6 1319 1323 (Pubitemid 29282934)
174. Hernndez A. M., Toledo D., Martnez D., Grin T., Brito V., Macas A., Alfonso S., Rondn T., Surez E., Vzquez A. M., Pérez R., Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody Journal of Immunology 2008 181 9 6625 6634
175. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., Jeannin J. F., Coudert B., Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? British Journal of Cancer 2006 94 2 259 267 (Pubitemid 43151545)
176. Shak S., Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer Seminars in Oncology 1999 26 4 71 77 (Pubitemid 29411435)
177. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A., Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes Journal of Experimental Medicine 1982 155 6 1823 1841 (Pubitemid 12074218)
178. Rosenberg S. A., Lotze M. T., Muul L. M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer The New England Journal of Medicine 1985 313 23 1485 1492 (Pubitemid 16212345)
179. Rosenberg S. A., Lotze M. T., Yang J. C., Topalian S. L., Chang A. E., Schwartzentruber D. J., Aebersold P., Leitman S., Linehan W. M., Seipp C. A., White D. E., Steinberg S. M., Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer Journal of the National Cancer Institute 1993 85 8 622 632 (Pubitemid 23120507)
180. Al-Moundhri M., O'Brien M., Souberbielle B. E., Immunotherapy in lung cancer British Journal of Cancer 1998 78 3 282 288 (Pubitemid 28336410)
181. Schiller J. H., Morgan-Ihrig C., Levitt M. L., Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer American Journal of Clinical Oncology 1995 18 1 47 51
182. Scudeletti M., Filaci G., Imro M. A., Motta G., Di Gaetano M., Pierri I., Tongiani S., Indiveri F., Puppo F., Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer Cancer Immunology Immunotherapy 1993 37 2 119 124 (Pubitemid 23175047)
183. Rosenberg S. A., Spiess P., Lafreniere R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 1986 233 4770 1318 1321 (Pubitemid 16002234)
184. Melioli G., Ratto G. B., Ponte M., Guastella M., Semino C., Fantino G., Tassara E., Pasquetti W., Mereu C., Merlo F., Reggiardo G., Morasso G., Santi L., Moretta L., Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study Journal of Immunotherapy 1996 19 3 224 230 (Pubitemid 26234616)
185. Meta M., Ponte M., Gustella M., Semino C., Pietra G., Ratto G. B., Melioli G., Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small cell lung cancer Cancer Immunology Immunotherapy 1995 40 4 235 240
186. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357 (Pubitemid 46218728)
187. Gattinoni L., Powell D. J. Jr., Rosenberg S. A., Restifo N. P., Adoptive immunotherapy for cancer: building on success Nature Reviews Immunology 2006 6 5 383 393
188. Wrobel P., Shojaei H., Schittek B., Gieseler F., Wollenberg B., Kalthoff H., Kabelitz D., Wesch D., Lysis of a broad range of epithelial tumour cells by human T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition Scandinavian Journal of Immunology 2007 66 2-3 320 328 (Pubitemid 47063194)
189. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K. H., Spies T., Broad tumor-associated expression and recognition by tumor-derived T cells of MICA and MICB Proceedings of the National Academy of Sciences of the United States of America 1999 96 12 6879 6884 (Pubitemid 29274978)
190. Nakajima J., Murakawa T., Fukami T., Goto S., Kaneko T., Yoshida Y., Takamoto S., Kakimi K., A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous T cells European Journal of Cardio-thoracic Surgery 2010 37 5 1191 1197
191. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proceedings of the National Academy of Sciences of the United States of America 1993 90 8 3539 3543 (Pubitemid 23111402)
192. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F. S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M., Dranoff G., Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma Journal of Clinical Oncology 2003 21 4 624 630 (Pubitemid 46621895)
193. Nemunaitis J., Sterman D., Jablons D., Smith J. W., Fox B., Maples P., Hamilton S., Borellini F., Lin A., Morali S., Hege K., Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer Journal of the National Cancer Institute 2004 96 4 326 331 (Pubitemid 38256277)
194. Nemunaitis J., Jahan T., Ross H., Sterman D., Richards D., Fox B., Jablons D., Aimi J., Lin A., Hege K., Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Therapy 2006 13 6 555 562
195. Raez L. E., Cassileth P. A., Schlesselman J. J., Sridhar K., Padmanabhan S., Fisher E. Z., Baldie P. A., Podack E. R., Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer Journal of Clinical Oncology 2004 22 14 2800 2807 (Pubitemid 41079897)
196. Hrig H., Lee D. S., Conkright W., Divito J., Hasson H., LaMare M., Rivera A., Park D., Tine J., Guito K., Tsang K. W. Y., Schlom J., Kaufman H. L., Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule Cancer Immunology Immunotherapy 2000 49 9 504 514
197. Madan R. A., Bilusic M., Hodge J. W., A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA Journal of Clinical Oncology 2011 29 supplement, abstract no. 2604
198. Hollingsworth M. A., Swanson B. J., Mucins in cancer: protection and control of the cell surface Nature Reviews Cancer 2004 4 1 45 60 (Pubitemid 38082153)
199. Ramlau R., Quoix E., Rolski J., Pless M., Lena H., Lévy E., Krzakowski M., Hess D., Tartour E., Chenard M. P., Limacher J. M., Bizouarne N., Acres B., Halluard C., Velu T., A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer Journal of Thoracic Oncology 2008 3 7 735 744
200. Acres B., Quoix E., Ramlau R., Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010 Journal of Clinical Oncology 2009 27 15, supplement, abstract no. 3027
201. van der Bruggen P., Stroobant V., Vigneron N., Van den Eynde B., Peptide database. Cancer Immunity, http://www.cancerimmunity.org/peptidedatabase/ Tcellepitopes.htm
202. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., Kehoe M., MacLean G., Longenecker M., Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer Clinical Lung Cancer 2001 3 1 49 57 (Pubitemid 32904315)
203. Oji Y., Miyoshi S., Maeda H., Hayashi S., Tamaki H., Nakatsuka S. I., Yao M., Takahashi E., Nakano Y., Hirabayashi H., Shintani Y., Oka Y., Tsuboi A., Hosen N., Asada M., Fujioka T., Murakami M., Kanato K., Motomura M., Kim E. H., Kawakami M., Ikegame K., Ogawa H., Aozasa K., Kawase I., Sugiyama H., Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers International Journal of Cancer 2002 100 3 297 303 (Pubitemid 34728987)
204. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O. A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihira S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S. I., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., Sugiyama H., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890 (Pubitemid 39298502)
205. Gomi S., Nakao M., Niiya F., Imamura Y., Kawano K., Nishizaka S., Hayashi A., Sobao Y., Oizumi K., Itoh K., A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24- restricted and tumor-specific CTLs Journal of Immunology 1999 163 9 4994 5004 (Pubitemid 29501267)
206. Gohara R., Imai N., Rikimaru T., Yamada A., Hida N., Ichiki M., Kawamoto M., Matsunaga K., Ashihara J., Yano S., Tamura M., Ohkouchi S., Yamana H., Oizumi K., Itoh K., Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer Journal of Immunotherapy 2002 25 5 439 444
207. Vansteenkiste J., Zielinski M., Linder A., Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer Journal of Clinical Oncology 2007 25 18, supplement, abstract no. 7554
208. Sienel W., Varwerk C., Linder A., Kaiser D., Teschner M., Delire M., Stamatis G., Passlick B., Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study European Journal of Cardio-thoracic Surgery 2004 25 1 131 134 (Pubitemid 38019071)
209. Brichard V. G., Lejeune D., GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development Vaccine 2007 25 2 B61 B71
210. Barve M., Bender J., Senzer N., Cunningham C., Greco F. A., McCune D., Steis R., Khong H., Richards D., Stephenson J., Ganesa P., Nemunaitis J., Ishioka G., Pappen B., Nemunaitis M., Morse M., Mills B., Maples P. B., Sherman J., Nemunaitis J. J., Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer Journal of Clinical Oncology 2008 26 27 4418 4425
211. Sharma S. V., Bell D. W., Settleman J., Haber D. A., Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer 2007 7 3 169 181
212. Giaccone G., Rodriguez J. A., EGFR inhibitors: what have we learned from the treatment of lung cancer? Nature Clinical Practice Oncology 2005 2 11 554 561 (Pubitemid 41721815)
213. Vinageras E. N., de La Torre A., Rodrguez M. O., Ferrer M. C., Bravo I., Del Pino M. M., Abreu D. A., Brooks S. A., Rives R., Carrillo C. D. C., Dueas M. G., Viada C., Verdecia B. G., Ramos T. C., Marinello G. G., Dvila A. L., Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer Journal of Clinical Oncology 2008 26 9 1452 1458
214. Gonzlez G., Crombet T., Neninger E., Viada C., Lage A., Therapeutic vaccination with Epidermal Growth Factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials Human Vaccines 2007 3 1 8 13
215. Antonia S. J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., Bepler G., Simon G., Janssen W., Lee J. H., Menander K., Chada S., Gabrilovich D. I., Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clinical Cancer Research 2006 12 3 878 887 (Pubitemid 43259871)
216. Ciernik I. F., Berzofsky J. A., Carbone D. P., Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes Clinical Cancer Research 1996 2 5 877 882 (Pubitemid 26168940)
217. Chiappori A. A., Soliman H., Janssen W. E., Antonia S. J., Gabrilovich D. I., INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect Expert Opinion on Biological Therapy 2010 10 6 983 991
218. Hirschowitz E. A., Foody T., Kryscio R., Dickson L., Sturgill J., Yannelli J., Autologous dendritic cell vaccines for non-small-cell lung cancer Journal of Clinical Oncology 2004 22 14 2808 2815 (Pubitemid 41079898)
219. Hirschowitz E. A., Foody T., Hidalgo G. E., Yannelli J. R., Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells Lung Cancer 2007 57 3 365 372 (Pubitemid 47285427)
220. Zhou Q., Guo A. L., Xu C. R., An S. J., Wang Z., Yang S. Q., Wu Y. L., A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro Clinical and Experimental Immunology 2008 153 3 392 400
221. Um S. J., Choi Y. J., Shin H. J., Son C. H., Park Y. S., Roh M. S., Kim Y. S., Kim Y. D., Lee S. K., Jung M. H., Lee M. K., Son C., Choi P. J., Chung J., Kang C. D., Lee E. Y., Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer Lung Cancer 2010 70 2 188 194
222. Chaput N., Schartz N. E. C., André F., Taeb J., Novault S., Bonnaventure P., Aubert N., Bernard J., Lemonnier F., Merad M., Adema G., Adams M., Ferrantini M., Carpentier A. F., Escudier B., Tursz T., Angevin E., Zitvogel L., Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading totumor rejection Journal of Immunology 2004 172 4 2137 2146 (Pubitemid 38182359)
223. Segura E., Amigorena S., Théry C., Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses Blood Cells, Molecules, and Diseases 2005 35 2 89 93 (Pubitemid 41267034)
224. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S., Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes Nature Medicine 1998 4 5 594 600 (Pubitemid 28237359)
225. Viaud S., Théry C., Ploix S., Tursz T., Lapierre V., Lantz O., Zitvogel L., Chaput N., Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Research 2010 70 4 1281 1285
226. Nemunaitis J., Dillman R. O., Schwarzenberger P. O., Senzer N., Cunningham C., Cutler J., Tong A., Kumar P., Pappen B., Hamilton C., DeVol E., Maples P. B., Liu L., Chamberlin T., Shawler D. L., Fakhrai H., Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer Journal of Clinical Oncology 2006 24 29 4721 4730 (Pubitemid 46630936)
227. Jain R. K., Duda D. G., Clark J. W., Loeffler J. S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Clinical Practice Oncology 2006 3 1 24 40 (Pubitemid 43108832)
228. Tomasini P., Khobta N., Greillier L., Barlesi F., Ipilimumab: its potential in non-small cell lung cancer Therapeutic Advances in Medical Oncology 2012 4 2 43 50
229. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma The New England Journal of Medicine 2010 363 8 711 723
230. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D. B., Lau J. S., Zhu G., Tamada K., Chen L., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Research 2005 65 3 1089 1096 (Pubitemid 40216472)
231. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Celis E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Medicine 2002 8 8 793 800
232. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
233. Brown J. A., Dorfman D. M., Ma F. R., Sullivan E. L., Munoz O., Wood C. R., Greenfield E. A., Freeman G. J., Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production Journal of Immunology 2003 170 3 1257 1266 (Pubitemid 36139491)
234. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M., B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clinical Cancer Research 2004 10 15 5094 5100 (Pubitemid 39106851)
235. Perrot I., Blanchard D., Freymond N., Isaac S., Guibert B., Pacheco Y., Lebecque S., Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage Journal of Immunology 2007 178 5 2763 2769 (Pubitemid 46333153)
236. Sun Y., Wang Y., Zhao J., Gu M., Giscombe R., Lefvert A. K., Wang X., B7-H3 and B7-H4 expression in non-small-cell lung cancer Lung Cancer 2006 53 2 143 151 (Pubitemid 43994236)
237. Choi I. H., Zhu G., Sica G. L., Strome S. E., Cheville J. C., Lau J. S., Zhu Y., Flies D. B., Tamada K., Chen L., Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family Journal of Immunology 2003 171 9 4650 4654 (Pubitemid 37310581)
238. Dannull J., Su Z., Rizzieri D., Yang B. K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633 (Pubitemid 43121851)
239. Rech A. J., Mick R., Recio A., Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC) Journal of Clinical Oncology 2010 28 15, supplement, abstract no. 2508